Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gruppo di Ricerca GISSI
The Protocol is sponsored by an independent organization and partially supported by: AstraZeneca, Società Prodotti antibiotici, Sigma Tau, Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical evidence of heart failure according to the European Society of Cardiology guidelines (New York Heart Association class II-IV) (32)
Any left ventricular Ejection Fraction (EF) measured within 3 months from enrolment (if EF% \>40%, at least 1 hospital admission for Congestive Heart Failure(CHF) in the previous year)
No age limits
Any etiology
Informed consent (obtained before any study specific procedure)
You may not be if
Acute Myocardial Infarction, unstable angina or revascularization procedure within 1 month;
planned cardiac surgery, expected to be performed within 3 months;
congenital or primary valvular etiology;
known hypersensitivity to study treatments;
significant liver disease;
pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception;
any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol;
presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy;
treatment with any investigational agent within 1 month before randomization;
patients already on treatment with n-3 PUFA or statin for whom the prescription is confirmed.
current serum creatinine level \>2.5 mg/dL;
current ALT, AST level \>1.5 times the upper normal limit;
current CPK upper normal limits.
Clareo Health | GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF
